Phyto Ingredients Biopharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 67.44%
(FY 2023)
- Profit -31.99%
(FY 2023)
- Ebitda -0.22%
(FY 2023)
- Net Worth 53.86%
(FY 2023)
- Total Assets 91.74%
(FY 2023)
About Phyto Ingredients Biopharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashish Singh and Vipul Upadhyay serve as directors at the Company.
- CIN/LLPIN
U74999HR2016PTC066206
- Company No.
066206
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Oct 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Jhajjar, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Phyto Ingredients Biopharma Private Limited offer?
Phyto Ingredients Biopharma Private Limited offers a wide range of products and services, including Ayurvedic Powder and Medicinal Herbs, Herbal Powder, Brain & Nervous System Drugs, Antimigraine Drug, Ayurvedic & Herbal Extracts, Plant Extracts, Herbal Extracts, Essential & Aromatic Oils, Herb Oil, Root and Vegetable Extracts.
Who are the key members and board of directors at Phyto Ingredients Biopharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vipul Upadhyay  | Director | 04-Jun-2019 | Current |
| Ashish Singh | Director | 25-Oct-2016 | Current |
Financial Performance of Phyto Ingredients Biopharma.
Phyto Ingredients Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 67.44% increase. The company also saw a substantial fall in profitability, with a 31.99% decrease in profit. The company's net worth Soared by an impressive increase of 53.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Phyto Ingredients Biopharma?
In 2023, Phyto Ingredients Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Phyto Ingredients Biopharma?
Unlock and access historical data on people associated with Phyto Ingredients Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Phyto Ingredients Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Phyto Ingredients Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
